慢性粒细胞白血病;治疗;羟基脲;α干扰素_

26例慢性粒细胞白血病的临床分析

http://www.100md.com 《河北北方学院学报》 2006年第2期

慢性粒细胞白血病;治疗;羟基脲;α干扰素,,慢性粒细胞白血病;治疗;羟基脲;α干扰素,1资料与方法,3讨论,参考文献

     【摘要】目的：结合病历分析各种治疗慢性粒细胞白血病(CML)药物的特点，寻找适合基层医院应用的治疗方法。方法：本组CML病人26人，男18例，女8例，根据国内采用的诊断标准明确诊断，分别应用羟基脲,马利兰,甲异靛及合用α干扰素治疗。结果：应用羟基脲治疗的患者中10例达血液学完全缓解，4例部分缓解，1例未缓解；应用马利兰治疗的有3例达到血液学完全缓解，2例部分缓解，1例未缓解；应用甲异靛治疗的2人均达部分缓解；加用α干扰素治疗的3人生存期3~10年。结论:今后在CML病人的治疗中，应以达到细胞遗传学缓解为治疗目标，在目前基层医院条件下，首选干扰素加化学药物治疗。

    【关键词】慢性粒细胞白血病;治疗;羟基脲;α干扰素

    Clinical Analyse on Treating 26 Chronic Myelogenous Leukemia

    HUANG Weihong

    Internal Department,Beijing Yanhua Phoenix Hospital, Beijing, 102425, China

    【ABSTRACT】 Objective:To analyze the medicament features for treating all kinds of chronic myelogenous leukemia (CML), and seeks the therapeutic methods suitable for primary hospitals.Methods: 26 patients with CML are selected, among which 18 are male and 8 are female.According to the domestic diagnosis standard, the patients are treated by using hydroxyurea, myleran, meisoindigo and combined with αinterferon. Results: Among the patients treated by hydroxyurea，10 patients get hematological complete remission, 4 patients get partial remission, 1 patient doesnt get remission; 3 patients treated by using myleran obtain hematological complete remission, 2 patients are partial remission, and 1 patient doesnt get remission; 2 patients treated by meisoindigo all get partial remission; the lifetime of the three patients treated by adding αinterferon is 3~10 years.Conclusion: In the therapy for CML patients, cytogenetics remission will be treating target. According to the condition of primary hospitals, αinterferon combined with chemical medicines will be the preferred method in curing CML. ......

百拇医药网 http://www.100md.com/html/DirDu/2006/11/03/27/43/48.htm

您现在查看是摘要页，全文长 11500 字符。